[Neuroimmunomodulation in allergic rhinitis].

Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

Published: September 2021

The role of neuroimmunomodulation in allergic diseases is a research hotspot in recent years. Allergic rhinitis(AR) is caused by overactive immune response to a foreign antigen in nasal mucosa. Immune cells release inflammatory mediators(including histamine, cytokines and neurotrophins), which directly activate peripheral neurons to mediate nasal congestion, itching, sneezing, and other hyperresponsive symptoms. Upon activation, these peripheral neurons release neurotransmitters (including acetylcholine and norepinephrine) and neuropeptides(including calcitonin gene-related peptide, substance P and vasoactive intestinal peptide) that directly act on immune cells to drive allergic inflammation. Neuro-immune signaling may play a significant role in the pathophysiology of AR. Therefore, a better understanding of these cellular and molecular neuro-immune interactions may inspire the discovery of new targets and novel therapies.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10127821PMC
http://dx.doi.org/10.13201/j.issn.2096-7993.2021.09.021DOI Listing

Publication Analysis

Top Keywords

immune cells
8
peripheral neurons
8
[neuroimmunomodulation allergic
4
allergic rhinitis]
4
rhinitis] role
4
role neuroimmunomodulation
4
neuroimmunomodulation allergic
4
allergic diseases
4
diseases hotspot
4
hotspot years
4

Similar Publications

Role of immune cell homeostasis in research and treatment response in hepatocellular carcinoma.

Clin Exp Med

January 2025

Department of Thoracic Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.

Introduction Recently, immune cells within the tumor microenvironment (TME) have become crucial in regulating cancer progression and treatment responses. The dynamic interactions between tumors and immune cells are emerging as a promising strategy to activate the host's immune system against various cancers. The development and progression of hepatocellular carcinoma (HCC) involve complex biological processes, with the role of the TME and tumor phenotypes still not fully understood.

View Article and Find Full Text PDF

PMN-MDSCs are responsible for immune suppression in anti-PD-1 treated TAP1 defective melanoma.

Clin Transl Oncol

January 2025

Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510013, Guangdong, China.

Introduction: The transporter associated with antigen processing (TAP) is a key component of the classical HLA I antigen presentation pathway. Our previous studies have demonstrated that the downregulation of TAP1 contributes to tumor progression and is associated with an increased presence of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. However, it remains unclear whether the elevation of MDSCs leads to immune cell exhaustion in tumors lacking TAP1.

View Article and Find Full Text PDF

Therapeutic potential of Bacillus-derived lipopeptides in controlling enteropathogens and modulating immune responses to mitigate post-weaning diarrhea in swine.

Vet Res Commun

January 2025

Departamento de Microbiología e Inmunología, Facultad de Ciencias Exactas, Físico-Químicas y Naturales, Universidad Nacional de Río Cuarto, Ruta N 36 Km 601, Río Cuarto City, 5800, Córdoba, Argentina.

Post-weaning diarrhea (PWD) is a major concern for pig producers, as stress and early weaning increase susceptibility to enteropathogens like enterotoxigenic Escherichia coli (ETEC) and Salmonella enterica subsp. enterica serovar Typhimurium (S. Typhimurium).

View Article and Find Full Text PDF

Melanoma is an immunogenic tumor. The melanoma tumor immune microenvironment (TIME) is made up of a heterogenous mix of both immune and non-immune cells as well as a multitude of signaling molecules. The interactions between tumor cells, immune cells and signaling molecules affect tumor progression and therapeutic responses.

View Article and Find Full Text PDF

Background: Celiac disease (CeD) has shown an association with autoimmune disorders including vitiligo and alopecia areata (AA). Ritlecitinib, a JAK3 and TEC kinase family inhibitor, has been approved for treatment of patients with AA and is in late-stage development for vitiligo. Ritlecitinib inhibits cytotoxic T cells, NK cells, and B cells which play a role in the pathogenesis of CeD.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!